MAG antibody (AA 34-605)
Quick Overview for MAG antibody (AA 34-605) (ABIN7874086)
Target
See all MAG AntibodiesReactivity
Host
Clonality
Conjugate
Application
Clone
-
-
Binding Specificity
- AA 34-605
-
Purpose
- Siglec-4a Antibody / MAG / Myelin-associated glycoprotein
-
Purification
- Affinity purified
-
Immunogen
- A human recombinant partial protein (amino acids E34-R605) was used as the immunogen for the Siglec-4a antibody.
-
Isotype
- IgG2a
-
-
-
-
Application Notes
- Optimal dilution of the Siglec-4a antibody should be determined by the researcher.
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Buffer
- 0.5 mg/mL if reconstituted with 0.2 mL sterile DI water
-
Storage
- 4 °C,-20 °C
-
Storage Comment
- After reconstitution, the Siglec-4a antibody can be stored for up to one month at 4oC. For long-term, aliquot and store at -20oC. Avoid repeated freezing and thawing.
-
-
- MAG (Myelin Associated Glycoprotein (MAG))
-
Alternative Name
- Siglec-4a
-
Background
- MAG (Myelin-associated glycoprotein), also known as Siglec-4a, is a cell membrane glycoprotein that is a member of the SIGLEC family of proteins and is a functional ligand of the NOGO-66 receptor, NgR. It is though to be involved in the process of myelination. MAG is a sialic acid-binding SIGLEC protein and is a functional ligand for the NOGO receptor.The MAG gene is mapped on 19q13.12. Cleavage of GPI-linked proteins from axons protects growth cones from MAG-induced collapse, and dominant-negative NgR eliminates MAG inhibition of neurite outgrowth. MAG-resistant embryonic neurons were rendered MAG-sensitive by expression of NgR. MAG binds specifically to an NgR-expressing cell line in a GPI-dependent and sialic acid-independent manner. Experiments blocking NgR from interacting with MAG prevented inhibition of neurite outgrowth by MAG. In cultured human embryonic kidney(HEK) cells expressing the NOGO receptor, p75(NTR) was required for MAG-induced intracellular calcium elevation.
-
UniProt
- P20916
-
Pathways
- Neurotrophin Signaling Pathway
Target
-